cas12101-sup-0001-FigS1.tifimage/tif1645KFig. S1. Inhibition of VEGFR2 activity and its downstream signaling by TAK-593.
cas12101-sup-0002-FigS2.tifimage/tif1268KFig. S2. Inhibition of VEGF- and PDGF-driven proliferation by TAK-593.
cas12101-sup-0003-FigS3.tifimage/tif1192KFig. S3. Effect of TAK-593 on the proliferation of five human cancer cell lines and fibroblasts.
cas12101-sup-0004-FigS4.tifimage/tif1118KFig. S4. Body weight change during TAK-593 treatment in Fig. 2a.
cas12101-sup-0005-FigS5.tifimage/tif1210KFig. S5. Anti-tumor effect of TAK-593 in Fig. 4.
cas12101-sup-0006-FigS6.tifimage/tif2822KFig. S6. Representative images of CD31 and Ki-67 immunohistochemistry and TUNEL from A549 xenograft tumors treated with TAK-593.
cas12101-sup-0007-FigS7.tifimage/tif1185KFig. S7. Effect of TAK-593 on the HT-29 tumor growth prior to DCE-MRI shown in Fig. 6.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.